Table 1 Clinicopathological features of patients with CD20-positive NK/T-cell lymphoma described in present and previous reports
No. | Authors (yr.) | Diagnosis | Age (year)/ Gender | Clinical Presentation | Immunophenotype | Molecular analysis | Treatment | Outcome |
|---|---|---|---|---|---|---|---|---|
1 | Ando, et al. (2008) [26] | Extranodal NK/T cell ymphoma, nasal type | 71/Male (Japanese) | Ulcerative mass in the right thenar prominence and a subcutaneous mass in right inguinal region | CD20+, CD2+, CD3+, CD56+, TIA-1+, granzyme B+, CD4-, CD5-, CD7-, CD8-, CD10- | EBERs (+); TCR β (−); TCR γ(−); TCR δ (−); IgH (−) | Chemotherapy with CHOP, ESHAP, and L-asparaginase | Progressive disease without remission and death in 6 months |
2 | Gill, et al. (2010) [27] | Disseminated NK/T cell lymphoma | 25/Male, (Chinese) | Hypermetabolic lesion in right chest wall, head and neck lymph node, left adrenal gland, peritoneum, liver and the right anterior nasal cavity | CD20 focal +, CD2+, CD45RO+, CD56+, TIA-1+, CD4-, CD5-, CD8-, CD79a-, PAX5-, Oct2-, BOB.1-, CD138- | EBERs (+); TCR β (−); TCR γ(−); IgH (−) | Not reported | Not reported |
3 | Present case | Extranodal NK/T cell lymphoma, nasal type | 78/Female (Chinese) | A solid mass in the left nasal cavity for 10 years | CD20+, CD2+, CD3+, CD56+, CD8+, TIA-1+, granzyme B+, CD79a-, CD30-, PAX5-, CD138- | EBERs (+); TCR γ(−); IgH (−) | No treatment | 6-months follow-up, alive |